SIGA Technologies (SIGA) investor relations material

Company overview and strategic priorities

• Focuses on infectious diseases and global health security, with a primary emphasis on smallpox treatment and prevention.

• Operates as a fully integrated, commercial-stage pharmaceutical company with expertise in government contracting.

• Strategic priorities include expanding regulatory approvals, global partnerships, and moving into complementary therapeutic areas.

• Maintains a robust balance sheet with disciplined cash management and no debt.

Product platform and differentiation

• TPOXX (tecovirimat) is a highly targeted antiviral approved in the US, Canada, EU, UK, and Japan for smallpox treatment.

• Demonstrates strong efficacy and safety in both preclinical and clinical studies, with no serious adverse events reported.

• One of only two approved antivirals for orthopoxvirus treatment, with a differentiated mechanism targeting the VP37 protein.

• TPOXX is positioned as a foundational franchise with a track record of multi-year government contracts.

Market need and threat landscape

• Smallpox remains a significant global threat due to increased vulnerability, synthetic biology advances, and geopolitical risks.

• Vaccines alone are insufficient; comprehensive preparedness requires both vaccines and antivirals.

• Most of the current population is unvaccinated, increasing susceptibility to outbreaks.